ExCellThera’s ECT-001 cell therapy for patients with blood cancers and disorders requiring stem cell transplants has received a Priority Medicines designation from the European Medicines Agency (EMA).
ExCellThera gets EMA Priority Medicines designation for ECT-001 cell therapy
Previous
Previous
MCI Onehealth Closes $30 Million Initial Public Offering
Next
Next